Solta Medical, a maker of medical devices focused on liposuction, skin resurfacing and other aesthetic areas, will reorganize, slash jobs and may even sell itself in a bid to reverse slumping sales.
Shire is one of those companies that's always rumored to be a buyer or a seller. Not so long ago, it was setting up poison-pill protections against an unwanted suitor. Now, it has beat out Big Pharma with a deal for ViroPharma, the maker of rare disease drugs.
The Novartis sales have officially begun. The Swiss drugmaker has now agreed to sell its blood diagnostics business to Grifols, the Spanish healthcare company, for $1.7 billion. As analysts digest the news, they're already asking which unit will be next to go.
Quintiles declined to divulge financials when it signed up to buy Novella Clinical in August, but a regulatory filing reveals that the world's largest CRO spent $146.5 million upfront for the contractor, with more money on the line tied to milestones.
The buyout--at $50 a share--will add Cinryze for hereditary angioedema to Shire's product lineup along with the experimental drug maribavir for cytomegalovirus, one of 8 clinical-stage programs in the pipeline.
Salix Pharmaceuticals, the gastrointestinal drug specialist, has snapped up fellow specialty drugmaker Santarus in a $2.6 billion all-cash buyout.
Chile-based CFR Pharmaceuticals has hit a wall in its quest to buy the South African drugmaker Adcock Ingram. Though leading Adcock shareholders had backed the $1.3 billion deal, the company's largest investor said no go.
Amid a protracted slump in venture capital and an IPO boom that favors drug developers, medical device companies are looking elsewhere for funding, striking innovative deals and reaching out to potential acquirers much earlier than ever before.
Endo Health Solutions needs a shot in the arm, now that its lead drug Lidoderm faces generic competition. And Endo may have found just that. The has company inked a deal to buy Canada's Paladin Labs for $1.6 billion.
We know Reckitt Benckiser is shopping its pharma unit. We also know that Shire is scouting for deals. Does it follow that Shire may bid on RB Pharma? Logically, yes. Practically? Maybe.